Bień Ewa, Balcerska Anna, Ciesielski Dominik
Kliniki Pediatrii, Hematologii, Onkologii i Endokrynologii, Akademii Medycznej w Gdańsku.
Wiad Lek. 2004;57(1-2):8-11.
beta 2-Microglobulin (beta 2-M) measurement acts as an important diagnostic tool of some lymphoproliferative disorders in adults. Its significance as a marker of disease activity in pediatric malignancies has not been evaluated yet. The aim of this study was to determine the clinical significance of the pre-treatment serum levels of beta 2-M in children suffering from neoplastic disease. The study was conducted in 61 children (28 girls and 33 boys) aged from 2.0 to 16.9 years at the time of disease diagnosis. The study group consisted of 6 common types of childhood malignancies: acute lymphoblastic leukemia (ALL--22 patients), acute nonlymphoblastic leukemia (ANLL--3), Hodgkin's disease (HD--12), non-Hodgkin's lymphomas (NHL--6) and malignant solid tumors: Wilms' tumor (Tu Wilms--10) and soft tissue sarcomas (SA--8). The control group consisted of 30 healthy children. Different behavior of beta 2-Microglobulin levels depending on histological type of the neoplasm was observed. The pre-treatment levels of analyzed marker in children with lymphoproliferative disorders (acute leukemias and lymphomas) were significantly elevated as compared to the levels in the healthy controls (median: 2.90 vs. 2.05 mg/L, p < 0.001). On the contrary, in patients with malignant solid tumors (Wilms tumor and soft tissue sarcomas) the median levels of beta 2-M at diagnosis were within normal range. Elevated values of serum beta 2-M were stated in the majority (67%) of patients with lymphoproliferative disorders and in 39% of patients with malignant solid tumors.
beta 2-Microglobulin may serve as an additional diagnostic marker in children with leukemias and lymphomas. Measurement of serum beta 2-M seems to have no clinical value in the diagnostics of pediatric malignant solid tumors.
β2微球蛋白（β2-M）检测是成人某些淋巴增生性疾病的重要诊断工具。其作为儿童恶性肿瘤疾病活动标志物的意义尚未得到评估。本研究的目的是确定肿瘤性疾病患儿治疗前血清β2-M水平的临床意义。研究在61名疾病诊断时年龄为2.0至16.9岁的儿童（28名女孩和33名男孩）中进行。研究组包括6种常见的儿童恶性肿瘤类型：急性淋巴细胞白血病（ALL——22例患者）、急性非淋巴细胞白血病（ANLL——3例）、霍奇金病（HD——12例）、非霍奇金淋巴瘤（NHL——6例）以及恶性实体瘤：肾母细胞瘤（Wilms瘤——10例）和软组织肉瘤（SA——8例）。对照组由30名健康儿童组成。观察到β2微球蛋白水平因肿瘤组织学类型不同而表现各异。与健康对照组相比，淋巴增生性疾病（急性白血病和淋巴瘤）患儿分析标志物的治疗前水平显著升高（中位数：2.90对2.05mg/L，p<0.001）。相反，恶性实体瘤（肾母细胞瘤和软组织肉瘤）患者诊断时β2-M的中位数水平在正常范围内。大多数（67%）淋巴增生性疾病患者和39%恶性实体瘤患者的血清β2-M值升高。
β2微球蛋白可作为白血病和淋巴瘤患儿的辅助诊断标志物。血清β2-M检测在小儿恶性实体瘤诊断中似乎没有临床价值。
